Eli Lilly licenses Adimab antibody discovery and optimization tech

By Melissa Fassbender contact

- Last updated on GMT

Adimab is a Lebanon, NH-based antibody discovery technology provider. (Image: iStock/Svisio)
Adimab is a Lebanon, NH-based antibody discovery technology provider. (Image: iStock/Svisio)

Related tags: Corporation, Eli lilly

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York.

According to the company, the technology transfer expands an ongoing collaboration with Eli Lilly and Company, which was established in 2010.

As part of the agreement, Lilly will receive an exclusive, custom human antibody library, as well as a license to use the Adimab Platform in all therapeutic areas – without target restriction.

Additionally, Lilly has secured options to receive continued improvements to the Adimab Platform, including access to new antibody libraries.

Adimab will receive an undisclosed upfront fee and future payments dependent on achieving set preclinical and clinical milestones. The company will also receive royalties on any therapeutic products that result from the technology’s use.

Partnership activity

Adimab has established partnerships with 50 pharmaceutical and biotechnology companies over the past eight years and has also transferred and implemented its technology at Merck, Novo Nordisk, Biogen, and GSK. 

According to the company's mid-year partnership activity update, its most advanced program with partner Arsanis is currently in Ph II clinical trials.

New alliances this year include Anokion, Moderna Therapeutics, Mapp Biopharmaceutical, and Pionyr Immunotherapeutics, among others.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars